Modeling of Textures to Predict Immune Cell Status and Survival of Brain Tumour Patients

被引:1
|
作者
Chaddad, Ahmad [1 ]
Zhang, Mingli [2 ]
Hassan, Lama [1 ]
Niazi, Tamim [3 ]
机构
[1] Guilin Univ Elect Technol, Sch Artificial Intelligence, Guilin, Guangxi, Peoples R China
[2] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada
[3] McGill Univ, Lady Davis Inst Med Res, Montreal, PQ, Canada
关键词
Biomarkers; CNN; Immunotherapy; Radiomics; Survival; GLIOBLASTOMA; LANDSCAPE;
D O I
10.1109/ISBI48211.2021.9434053
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Radiomics has shown a capability for different types of cancers such as glioma to predict the clinical outcome. It can have a non-invasive means of evaluating the immunotherapy response prior to treatment. However, the use of deep convolutional neural networks (CNNs)-based radiomics requires large training image sets. To avoid this problem, we investigate a new imaging features that model distribution with a Gaussian mixture model (GMM) of learned 3D CNN features. Using these deep radiomic features (DRFs), we aim to predict the immune marker status (low versus high) and overall survival for glioma patients. We extract the DRFs by aggregating the activation maps of a pre-trained 3D-CNN within labeled tumor regions of MRI scans that corresponded immune markers of 151 patients. Our experiments are performed to assess the relationship between the proposed DRFs, three immune cell markers (Macrophage M1, Neutrophils and T Cells Follicular Ik!per), and measure their association with overall survival. Using the random forest (RF) model, DRFs was able to predict the immune marker status with area under the ROC curve (AUC) of 78.67, 83.93 and 75.67% for Macrophage M1, Neutrophils and T Cells Follicular Helper, respectively. Combined the immune markers with DRFs and clinical variables, KaplanMeier estimator and Log-rank test achieved the most significant difference between predicted groups of patients (short-term versus long-term survival) with p =4.31 x10(-7) compared to p = 0.03 for Immune cell markers, p = 0.07 for clinical variables, and p =1.45 x10(-5) for DRFs. Our findings indicate that the proposed features (DRFs) used in RF models may significantly consider prognosticating patients with brain tumour prior to surgery through regularly acquired imaging data.
引用
收藏
页码:1067 / 1071
页数:5
相关论文
共 50 条
  • [31] Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients
    B Weigelt
    A J Bosma
    A A M Hart
    S Rodenhuis
    L J van't Veer
    British Journal of Cancer, 2003, 88 : 1091 - 1094
  • [32] Systemic inflammatory markers and serum lactate dehydrogenase predict survival in patients with Wilms tumour
    Kunc, Michal
    Gabrych, Anna
    Dulak, Dominika
    Hasko, Karolina
    Styczewska, Malgorzata
    Szmyd, Dagmara
    Nilsson, Kristoffer
    Iwinski, Marek
    Sobocinska-Mirska, Agata
    Sawicka-Zukowska, Malgorzata
    Krawczyk, Malgorzata A.
    Bien, Ewa
    ARCHIVES OF MEDICAL SCIENCE, 2022, 18 (05) : 1253 - 1261
  • [33] Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients
    Weigelt, B
    Bosma, AJ
    Hart, AAM
    Rodenhuis, S
    van't Veer, LJ
    BRITISH JOURNAL OF CANCER, 2003, 88 (07) : 1091 - 1094
  • [34] Can Nutritional Status Predict Overall Survival in Patients with Advanced Non-Small Cell Lung Cancer?
    Seo, Youngkwang
    Eo, Wankyu
    Kim, Sehyun
    Shim, Bumsang
    Lee, Sookyung
    NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2019, 71 (07): : 1108 - 1117
  • [35] Deciphering Immune-Associated Genes to Predict Survival in Clear Cell Renal Cell Cancer
    Hu, Daixing
    Zhou, Mi
    Zhu, Xin
    BIOMED RESEARCH INTERNATIONAL, 2019, 2019
  • [36] Socioeconomic status does not affect survival in patients with brain metastases
    Nagtegaal, S.
    Claes, A.
    Elias, S. G.
    Snijders, T. J.
    Verkooijen, H. M.
    Verhoeff, J. J. C.
    RADIOTHERAPY AND ONCOLOGY, 2020, 152 : S288 - S289
  • [37] Vitamin D status after colorectal cancer diagnosis and patient survival according to immune response to tumour
    Hamada, Tsuyoshi
    Liu, Li
    Nowak, Jonathan A.
    Mima, Kosuke
    Cao, Yin
    Ng, Kimmie
    Twombly, Tyler S.
    Song, Mingyang
    Jung, Seungyoun
    Dou, Ruoxu
    Masugi, Yohei
    Kosumi, Keisuke
    Shi, Yan
    da Silva, Annacarolina
    Gu, Mancang
    Li, Wanwan
    Keum, NaNa
    Wu, Kana
    Nosho, Katsuhiko
    Inamura, Kentaro
    Meyerhardt, Jeffrey A.
    Nevo, Daniel
    Wang, Molin
    Giannakis, Marios
    Chan, Andrew T.
    Giovannucci, Edward L.
    Fuchs, Charles S.
    Nishihara, Reiko
    Zhang, Xuehong
    Ogino, Shuji
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : 98 - 107
  • [38] Baseline tumour measurements predict survival in advanced non-small cell lung cancer
    Gerber, D. E.
    Dahlberg, S. E.
    Sandler, A. B.
    Ahn, D. H.
    Schiller, J. H.
    Brahmer, J. R.
    Johnson, D. H.
    BRITISH JOURNAL OF CANCER, 2013, 109 (06) : 1476 - 1481
  • [39] Baseline tumour measurements predict survival in advanced non-small cell lung cancer
    D E Gerber
    S E Dahlberg
    A B Sandler
    D H Ahn
    J H Schiller
    J R Brahmer
    D H Johnson
    British Journal of Cancer, 2013, 109 : 1476 - 1481
  • [40] Proliferation and microvascular density predict survival in patients with brain metastases of non-small cell lung cancer
    Berghoff, A.
    Ilhan-Mutlu, A.
    Woehrer, A.
    Hackl, M.
    Widhalm, G.
    Hainfellner, J. A.
    Dieckmann, K.
    Zielinski, C. C.
    Birner, P.
    Preusser, M.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S792 - S793